Alzamend Neuro Collaborates with Massachusetts General Hospital for Pioneering Phase II Trial of AL001 in PTSD Treatm...
Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company, has announced a significant partnership with Massachusetts General Hospital (MGH) to initiate a Phase II clinical trial for AL001, a next-...
Aug 19, 2024
• Major Pharmaceutical Preparations Industry
Business Update
NasdaqMassachusetts General Hospital Inc Inc Massa
